All In Biotech

Drug Trial Radar · NCT07151872

Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

A Phase II Clinical Study to Evaluate the Efficacy and Safety of QLS31905 for Injection in Combination With Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

Last checked: Nov 19, 2026Latest source record: Sep 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Sep 2025

Primary completion

Oct 2026

Study completion Oct 2026

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter Phase II clinical study aimed at evaluating the efficacy, safety, PK profile, and immunogenicity of QLS31905 for Injection combined with Chemotherapy ± QL2107 in Patients with CLDN18.2-positive Advanced Biliary Tract Cancer

Conditions

  • CLDN18.2-positive Advanced Biliary Tract Cancer

Interventions

  • QLS31905 for InjectionDrug

    QLS31905 for Injection

  • Gemcitabine Hydrochloride for InjectionDrug

    Gemcitabine Hydrochloride for Injection

  • Cisplatin for InjectionDrug

    Cisplatin for Injection

  • QL2107 InjectionDrug

    QL2107 Injection

  • Oxaliplatin InjectionDrug

    Oxaliplatin Injection

  • Capecitabine TabletsDrug

    Capecitabine Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR (Objective Response Rate)Time frame: Approximately 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.